XEROSTOMIA Clinical Trial
Official title:
Multicenter, Controlled Parallel Groups Trial to Evaluate the Efficacy, Safety and Acceptability of OGT Oromucosal Spray Versus a Saliva Substitute in the Treatment of Xerostomia in Geriatrics
The primary objective of the trial is to evaluate the efficacy, safety and clinical acceptability of OGT oromucosal spray in the relief of symptoms and signs of xerostomia in comparison with a saliva substitute (European Medical Device).
Xerostomia is excessive dryness of the mouth. It is due to insufficient (hyposialism) or
inexistent (asialia) saliva secretion.
There are many causes. Transitory xerostomia may occur in the presence of anxiety (stage
fright, fear or dehydration). Prolonged xerostomia is most often related to a systemic
disease, certain medicines or to radiotherapy of the head or neck.
Xerostomia is often accompanied by buccal symptoms and signs such as impaired sense of
taste, fetid breath and mouth ulcers, and it disturbs functions such as speech, chewing and
swallowing. Because of reduced salivary secretion, there is disturbance of the microbial
colonization of the buccal cavity, increased demineralization and decreased remineralization
of the teeth, impaired retention of dentures, dehydration of the mucosa and reduced
lubrication of the buccal mucosa. These complications may take the form of dental caries,
candidiasis, atrophy and feelings of burning of the mucosa, difficulty retaining dentures,
impaired speech and swallowing and impression of decreased or impaired sense of taste.
Xerostomia has significant harmful effects on the buccal cavity and on the quality of life
of patients.
Xerostomia prevalence rates of the order of 18-61% have been reported in the elderly. These
rates are generally higher in women that in men and increase with age. They are also higher
in populations in institutions and in those taking multiple medications. Wearing a denture,
stress and other psychological factors have also been suggested as factors increasing risk
or or worsening xerostomia.
Treatments of xerostomia are saliva substitutes and saliva stimulants.
OGT Spray is neither a substitute nor stimulant of saliva.
OGT Spray is a solution for oromucosal spray which has lubricant and protective actions.
The aim of the study was to demonstrate that OGT Spray (oral lubricant) was effective in the
subjective relief of dry mouth symptoms and objective signs of dry mouth in elderly.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05342272 -
Comparison of Gum® HydralTM Moisturizing Gel and Biotene® Oral Gel in Dry Mouth Sensation Reduction
|
Phase 3 | |
Completed |
NCT03302676 -
The Use of Chewing Gum for Xerostomia and Hyposalivation After Radiotherapy for Oral and Oropharyngeal Tumors
|
N/A | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Completed |
NCT01272570 -
Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors
|
N/A | |
Completed |
NCT00656513 -
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00911768 -
Effect of Korean Red Ginseng (KRG) on Dry Mouth
|
Phase 4 | |
Completed |
NCT00332618 -
Efficacy Study of Oxygenated Glycerol Triesters to Treat Xerostomia
|
Phase 2 | |
Completed |
NCT03494985 -
A Clinical Study to Evaluate the Efficacy of Three Dry Mouth Relief Products Versus Water
|
N/A | |
Completed |
NCT05058430 -
SaliPen Human Factors Study for OTC Labeling
|
N/A | |
Recruiting |
NCT02705937 -
Early Phase Study Comparing the Effectiveness of a Dairy Product With the Reference Treatment Aequasyal® on Dry Mouth Symptoms in Patients Suffering From Xerostomia Caused by Psychotropic Medications.
|
N/A | |
Completed |
NCT05247008 -
Effectiveness of Thyme Honey in Management of Xerostomia in ESRD
|
N/A | |
Recruiting |
NCT03632096 -
Photobiomodulation in Salivary Production of Patients With Xerostomy
|
Phase 2 | |
Not yet recruiting |
NCT04323384 -
The Effect of Biotene® on the Symptoms of Xerostomia and Mastication and Swallowing
|
N/A | |
Not yet recruiting |
NCT03530735 -
Finger-prick Autologous Blood (FAB) for Use in Dry Mouth
|
N/A | |
Active, not recruiting |
NCT03176368 -
Coconut Oil: Managing Radiation-Induced Xerostomia
|
N/A | |
Enrolling by invitation |
NCT06122636 -
Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC
|
N/A | |
Completed |
NCT03611283 -
Topical Management of Xerostomia With Dry Mouth Products
|
N/A | |
Completed |
NCT02682199 -
Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation
|
||
Withdrawn |
NCT01960101 -
Development of a Milk Product Substitution for Patients Suffering From Xerostomia Caused by Medication
|
N/A | |
Completed |
NCT02317172 -
Efficacy of Novel Edible Gel-based Artificial Saliva in Thai Geriatric Populations With Systemic Diseases
|
N/A |